Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TAMUC1 Antibody in DS-3939 from Glycotope GmbH
Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the antitumor-associated mucin-1 (TA-MUC1) antibody, gatipotuzumab.